Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for RMD and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for RMD and 80,000+ other tickers.
See exactly how RMD's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for RMD and 80,000+ other tickers.
ResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its extensive product range addresses a variety of respiratory disorders, encompassing advanced medical and consumer technologies, ventilation devices, diagnostic equipment, mask systems for both clinical and personal use, headgear, and related accessories, alongside dental devices. ResMed also provides…
Baader Bank Aktiengesellschaft decreased its stake in shares of ResMed Inc. (NYSE: RMD) by 61.7% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,768 shares of the medical equipment provider's stock after selling 7,696 shares during the quarter. Baader
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
RMD's MatrixCare sale sharpens its focus on sleep, breathing and connected care while freeing resources for AI-powered digital health.
ResMed Inc. (NYSE:RMD) agreed to sell its MatrixCare business on Tuesday to Frazier Healthcare Partners, a private equity firm focused exclusively on health care, for $490 million.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.